BLRX - BioLineRx down 12% despite Q3 earnings beat

BioLineRx (BLRX) Q3 results:Revenues: $0; R&D Expense: $3.5M (-37.5%); Net loss: ($4.6M) (-17.9%); loss/share: ($0.02) (+33.3%); Quick Assets: $20.8M ; CF Ops: ($17.8M) (+3.5%).During the quarter, the company reported interim analysis for Phase 2b BLAST study in consolidation AML that did not demonstrate statistically significant effect in primary endpoint; study will not continue and the company is exploring alternative development options in AML.Upcoming expected milestones: Phase 2a COMBAT/KEYNOTE-202 study in PDAC on track to report full results, including progression free survival and overall survival dataexpected by the end of 2020.Final results from the Phase 3 GENESIS trial in SCM in the 1H 2021.Preliminary results of the Phase 1b study in ARDS expected in the 1H 2021.Initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors expected in the 2H 2021.Data from the Columbia University-initiated study of motixafortide in combination with LIBTAYO and chemotherapy in first-line PDAC expected

For further details see:

BioLineRx down 12% despite Q3 earnings beat